NEW YORK (GenomeWeb) – CRISPR Therapeutics late on Friday filed for an initial public offering on the Nasdaq.

In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million of its common stock. The timing of the offering, as well as the number and price of shares to be sold, were not disclosed. Citigroup, Piper Jaffray, Barclays, and Guggenheim Securities are underwriting the transaction.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.